Oral Supplementation With Probiotic L. reuteri NCIMB 30242 Increases Mean Circulating 25-Hydroxyvitamin D: A Post Hoc Analysis of a Randomized Controlled Trial
Mitchell L. Jones*,
Christopher J. Martoni* and
Biomedical Technology and Cell Therapy Research Laboratory (M.L.J., S.P.), Department of Biomedical Engineering and Physiology, Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, Montreal, Quebec H3A 2B4, Canada; and Micropharma Limited (M.L.J., C.J.M., S.P.), Montreal, Quebec H2W 2R2, Canada
Address all correspondence and requests for reprints to: Satya Prakash, Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, 3775 University Street, Montreal, Quebec H3A2B4, Canada. E-mail: satya.prakash at mcgill.ca.
↵* M.L.J. and C.J.M. made equal contribution.
Context: Low serum 25-hydroxyvitamin D is a risk factor for osteoporosis, cardiovascular disease, diabetes, and cancer. Disruption of noncholesterol sterol absorption due to cholesterol-lowering therapies may result in reduced fat-soluble vitamin absorption.
Objective: We have previously reported on the cholesterol-lowering efficacy and reduced sterol absorption of probiotic bile salt hydrolase active Lactobacillus reuteri NCIMB 30242; however, the effects on fat-soluble vitamins was previously unknown and the objective of the present study.
Design, Settings, Patients, and Intervention: The study was double-blind, placebo-controlled, randomized, parallel-arm, multicenter lasting 13 weeks. A total of 127 otherwise healthy hypercholesterolemic adults with low-density lipoprotein-cholesterol >3.4 mmol/L, triglycerides <4.0 mmol/L, and body mass index of 22 to 32 kg/m2 were included. Subjects were recruited from 6 private practices in Prague, Czech Republic, and randomized to consume L. reuteri NCIMB 30242 or placebo capsules over a 9-week intervention period.
Outcome measures: The primary outcome measure was the change in serum low-density lipoprotein-cholesterol over the 9-week intervention. Analysis of fat-soluble vitamins at weeks 0 and 9 were performed post hoc.
Results: There were no significant differences between L. reuteri NCIMB 30242 and placebo capsule groups in serum vitamin A, vitamin E, or β-carotene or dietary intake over the intervention period (P > .05). L. reuteri NCIMB 30242 increased serum 25-hydroxyvitamin D by 14.9 nmol/L, or 25.5%, over the intervention period, which was a significant mean change relative to placebo of 17.1 nmol/L, or 22.4%, respectively (P = .003).
Conclusions: To our knowledge, this is the first report of increased circulating 25-hydroxyvitamin D in response to oral probiotic supplementation.
- All items in category Predict Vitamin D
Amazon sells 25 different versions of the probiotic.
Even if the probiotic only costs 20 cents per capsule, taking 22% more vitamin D is far less expensive
PDF is attached at the bottom of this pageProbiotic (Lactobacillus reuteri) increased vitamin D levels 22 percent – RCT July 2013
3402 visitors, last modified 01 Dec, 2013,